BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer IndicationGlobeNewsWire • 10/19/23
Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 BillionInvestors Business Daily • 10/16/23
Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting DemandForbes • 10/16/23
BioNTech's stock sinks after disclosing expected charge of up to nearly $1 billion resulting from Pfizer's write offs of COVID productsMarket Watch • 10/16/23
Pfizer shares fall on guidance cut, weighing on BioNTech and Moderna stocks, and other shares on the moveMarket Watch • 10/16/23
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023GlobeNewsWire • 10/16/23
The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?The Motley Fool • 10/11/23
3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall StreetThe Motley Fool • 10/01/23
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 VaccineGlobeNewsWire • 09/28/23
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?The Motley Fool • 09/20/23
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI's 100 Days MissionGlobeNewsWire • 09/18/23